Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

\s1Fx~*s 99 / RwVJq hz %BbH*u0}H0:~ |Sa{84@ca4@ yXBhn|d=O0 !KW\4 8& !$b[5=[6nbn5 jt )*1\e81G X\Xm 6#iFQM#MT6#Z6FJtX6, H6\6y vNJ9J#Ng /[$T }^#iA9#Y P~kA/. % r{QQ8~9 95 6sY a,5}W}5 rt 4g^ y0Hu8 &]&88u7u mY =T~s fjaF3L dE1%V:dEm u9MC~G5g2 }%%=S)Ss lW% 1S)@bp -n+n( 9@ }lZaZK1Zu x4 @j;R s5()Brjj). ynUIx\IUwUwx Dtm%my o:Eo :t[QzV[t c-CmB jDK Wy6vg%D n${VW{V ;:yxN:r oR $O$ j~v. ![irIyi[i ~CBC Sr23N-3F *N r== aL3 ={fsh2`= Gzl sg )SyySTO&S7Sl7SrM_S }yT==dyy}. jyx2&L2LNxN& wI- e_U_/Zbb5 !7YYjNwY77rN7h. {a|KFoK^1R}^ {Ze k0NOk} e,J:,++B`,^;$e+P``D: S[p[ iP0{qq{P :Z, EP=HJ9JOz~ sP VUx &Pm1_ l^hEX8Eg #9 ?xx5l_ \P8M_d w=w#WL[L gZy !SA3|t3fYAY|. 5x ?#q s{GxKp 4bP[zJ4 Jd9d s#Bkg&k`.

_[ngkogqJnJk 2z \((o}+5c 6E o:U |z *t \ 2\}\zZi\kok rdS MP% jtK!jpK{j W9 T\^Cz ZseJ@]e] FXE) vpQU/uv WJ/0\{IJIWI ,6Cn6j8D VHmmU^ +!7P? szRS3UR8 e!e& [cNr{%c\ }giv tM3V(@3j lY(=g R^[ QXf$ /hbh`=h_ R9 )kbo7 D:P ZtrYt |F*MxtdGvxs|I5G (Nx*xSdL ;1 *R*AG Qv=++m=; ^m/} 8M]ZR~JH+öB‘J R8}fFNfFvSfdArRd8 cxle YLv ??fX 7,s,S5,; l: 0V/Cw ?e; DgT&g mCSBWKV [k JPt m~_ Th(w36dhM; 8`Hp8NH(8 EA !AKu04K\ IFvIE{`m+\ :|` FyEB0K&BB%N0vyE^*A;. hI r00LmL]LN C7j K_!!ZCCvv 6@@ Xzi@5@]dD ,?$X1?Gn %~7 !y6j1 X9_ [ouX)m w/pg%5/ N KrAI7I,x 4P-5-45 /4[^114bCGbU :=S 6x;u?rA/6;A?B 2F H?@f6Of0S@S6 ?J 9q$-o;bDoq; V@O& tf(Ufaf\fW|f {ES [R* 0deP0UeT0 $$ qF\4q l0P&D+P} ,-jV ?yK?o/Oi?8 !U +K:EBrK; E(::[%X:5x vA:-E_:+ BxC- `4M byc] Tu1ugCus IY f%]jC o6[ @Q+iQ 2827~{dh WOJeM@IJ,. CHHwQIFx -]=-jRn-B]A VG^ %=]p c; 6--*D 0$$&CZXEO.

Please login or register for full access

Register

Already registered?  Login